PT-141

Originally developed from the peptide melanotan II, this melanocortin receptor agonist represents one of the few peptides to achieve FDA approval for sexual health applications. Unlike typical sexual dysfunction treatments that focus on blood flow, bremelanotide targets neurological pathways in the brain. Clinical researchers and hormone specialists frequently investigate its unique mechanism for treating hypoactive sexual desire disorder, particularly in premenopausal women.

Bremelanotide binds to melanocortin-4 receptors located in specific brain regions that control sexual motivation and arousal. Rather than affecting blood vessels like Viagra-type medications, it essentially 'switches on' the neural circuits responsible for sexual desire at the source. This central nervous system approach explains why it can increase libido in both men and women, regardless of physical arousal capacity.